Irish journal of medical science · 2026
Efficacy and safety of micropulse transscleral cyclophotocoagulation in glaucoma: a two-year retrospective audit cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eissa Mahmoud, Mohamed Abdulrahman, Dahshan Salma, Elsayed Ahmed
Аннотация
PURPOSE: To retrospectively evaluate the efficacy and safety of Micropulse Transscleral Cyclophotocoagulation (MP-TSCPC) in reducing intraocular pressure (IOP) and the number of glaucoma medications in patients with different types of glaucoma over a two-year period.
METHODS: This retrospective audit included 52 eyes from 32 patients treated with MP-TSCPC at Mountainhall Treatment Centre, Dumfries, UK, between August 2021 and September 2023. Standard treatment parameters included 2500 mW power applied for 10 s per quadrant across 9 cycles. Primary outcomes were changes in IOP and the number of glaucoma medications. Secondary outcomes included postoperative complications and changes in the mean deviation of the visual field (MD).
RESULTS: The mean preoperative IOP was 21.4 mmHg, which significantly decreased postoperatively to 11.9 mmHg at 4 weeks, 12.75 mmHg at 3 months, 13.4 mmHg at 1 year, and 14.03 mmHg at 2 years. The median IOP reduction at 1 year was 5.0 mmHg with statistical significance (p < 0.0001). The average number of topical medications declined from 2.21 eye drops to 1.58 eye drops. No statistically significant change was observed in visual field MD (p = 0.4838), though disease progression appeared to stabilize (mean MD: -7.1 dB). Complications were infrequent and included mild anterior uveitis (n = 12), cystoid macular edema, recurrence of herpetic keratitis and severe ocular inflammation (n = 1).
CONCLUSION: MP-TSCPC is a safe and effective procedure for medium-term IOP control, particularly in patients with primary open-angle glaucoma. It significantly reduces IOP and medication dependency, with a low complication profile. However, outcomes are more variable in secondary glaucoma, especially uveitic cases. These findings support the growing role of MP-TSCPC as a minimally invasive treatment option for glaucoma.
METHODS: This retrospective audit included 52 eyes from 32 patients treated with MP-TSCPC at Mountainhall Treatment Centre, Dumfries, UK, between August 2021 and September 2023. Standard treatment parameters included 2500 mW power applied for 10 s per quadrant across 9 cycles. Primary outcomes were changes in IOP and the number of glaucoma medications. Secondary outcomes included postoperative complications and changes in the mean deviation of the visual field (MD).
RESULTS: The mean preoperative IOP was 21.4 mmHg, which significantly decreased postoperatively to 11.9 mmHg at 4 weeks, 12.75 mmHg at 3 months, 13.4 mmHg at 1 year, and 14.03 mmHg at 2 years. The median IOP reduction at 1 year was 5.0 mmHg with statistical significance (p < 0.0001). The average number of topical medications declined from 2.21 eye drops to 1.58 eye drops. No statistically significant change was observed in visual field MD (p = 0.4838), though disease progression appeared to stabilize (mean MD: -7.1 dB). Complications were infrequent and included mild anterior uveitis (n = 12), cystoid macular edema, recurrence of herpetic keratitis and severe ocular inflammation (n = 1).
CONCLUSION: MP-TSCPC is a safe and effective procedure for medium-term IOP control, particularly in patients with primary open-angle glaucoma. It significantly reduces IOP and medication dependency, with a low complication profile. However, outcomes are more variable in secondary glaucoma, especially uveitic cases. These findings support the growing role of MP-TSCPC as a minimally invasive treatment option for glaucoma.